Early Surgically-Induced Menopause Linked with Cognitive Decline

Article

Women with early, surgically-induced menopause had greater incidence of neurological problems, including declining cognitive function and early indicators of Alzheimer’s disease in a study reported at the American Academy of Neurology meeting.

Women with early, surgically-induced menopause had greater incidence of neurological problems, including declining cognitive function and early indicators of Alzheimer’s disease, according to a report at the American Academy of Neurology’s Annual Meeting.

Compared with women who had normal menopause, a young age at surgically-induced menopause was significantly associated with decline in memory; cognition; Alzheimer’s pathology; and neuritic plaques, which, in large numbers, are characteristic of Alzheimer’s disease. No significant association with Alzhemier’s disease itself was shown, however.

Lead author Riley Bove, MD, of Harvard Medical School, noted that estrogen is neuroprotective and that the loss of estrogen at an early age may “increase the risk of cognitive decline.”

Hormone replacement therapy (HRT) had no significant effect on cognitive decline, regardless of the duration of use or time of initiation.
 

References:

Bove R, et al "Early surgical menopause is associated with a spectrum of cognitive decline" AAN 2013; Abstract IN8-2.004.

Recent Videos
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.